White Papers2018-07-25T09:42:18+00:00

White Papers

TrialCard offers a number of resources that address current trends in the pharmaceutical industry.

Check the box next to the items you would like to receive, then scroll to the bottom of the page and click Submit.

In a reported effort to reduce health plan spend for specialty drugs, pharmacy benefit managers have begun promoting “co-pay accumulator” programs to health plan sponsors. The effect of these programs is often to shift much of the cost burden for expensive specialty drugs toward patients and manufacturers. This white paper takes a deep dive into these programs and discusses how an affected brand and its patients should respond.

On October 9, 2017, California Governor Jerry Brown signed AB 265 into law. This landmark piece of legislation modified the California Health and Safety Code to prohibit the “offering” of any discount, product voucher, or other out-of-pocket cost reduction tool by drug manufacturers when there is an FDA-approved therapeutic equivalent. As a result, many manufacturers are worried about the impact to their brands. TrialCard has the expertise and technology to solve your brand challenges in California in compliance with the new law. Our solution will give you a partner, not just a vendor.

Why a Qualitative Lead Generation Approach Is a Must-Have Component of Any Orphan Drug Sales Strategy

How Properly Timed, Targeted Engagement Tactics Can Increase Adherence and Brand Revenue

This white paper examines the success of specialty medications that have coupled their buy-and-bill cost-sharing assistance program with a fully integrated HUB solution to support the patient with their affordability needs as well as with infusion/injection administration, appointment scheduling support, and care coordination.

TrialCard has a proven track record of successfully transitioning existing patient access and affordability programs while improving the patient experience and growing brands. This case study examines the unique co-pay program design and transition strategy TrialCard developed and executed for a top allergy brand. These improvements helped maximize program impact, resulting in total incremental revenue exceeding 24M.

Co-Pay Support Programs provide the entrée to better outcomes precisely because it’s one of the best vehicles for engaging patients. Because patients regularly come back to Co-Pay Support Programs when it’s time for a refill, they offer tremendous leverage and opportunity to engage with patients on more matters than simple Co-Pay and financial assistance: be that for behavioral profiling, adherence support, education, or real-world evidence.

How the multi-tiered formularies of ACA QHP’s place the burden of cost on the patient and limit a brand’s access to patients.

By utilizing data to understand specific reasons for non-adherence and the ideal timing, content, and channel for intervention, manufacturers can create more successful patient engagement strategies that help influence a shift toward better compliance with therapy.

Key measures that TrialCard has invested in to ensure that we can provide our clients the assurance that their promotions are generating positive returns

As the healthcare landscape moves increasingly toward outcome-based treatment approaches, the need to gather and analyze real-world outcome data has become paramount to gauging medication effectiveness and subsequently recruiting prescribers as brand advocates. This study outlines a feedback program that provides prescribers with patient results of their treatment experience in order to better inform their therapy recommendations. The program is designed to offer a unique value proposition to both patients and physicians to drive increased participation in their treatment.

TrialCard’s vision and strategic philosophy is to support branded pharmaceutical manufacturers in marketing medicines through the strategy, design, and execution of innovation solutions. The case study that follows demonstrates TrialCard’s ability to support a brand’s unique challenges with a customized solution.

Good analytics can catapult a program to greater levels of success. In this White Paper, discover the specific data points that identify and reduce the number of "walkaways" (i.e. patients who decide not to purchase a prescription).

While co-pay offset programs make medicines affordable for patients, they have benefits that go way beyond simply reducing prices. Using these programs to acquire and engage patients can lead to better adherence, but also to new connections with both physicians and pharmacies and multiple benefits to pharmaceutical manufacturers.

This white paper examines the complex challenge of transitioning a patient support program in an abbreviated time frame. In one example cited, TrialCard transitioned over 93,000 patients and onboarded 36 case managers in a shortened time period as compared to average program-transition time in the industry.

ROI is commonly regarded as the gold standard of business evaluation. Analysts, marketers, and investors alike all speak of those magical three letters as the consummate indicator of a project’s success. High ROI means money well spent, while a suboptimal ROI is a black mark and almost certain precursor to an effort’s termination. But in the co-pay savings program space, ROI only tells a small part of the story when judging a program’s overall effectiveness. A deeper dive into the data strongly suggests that there are additional evaluation measures that can help paint the full picture of a program’s value to the brand marketer.

Program optimization analyses use transactional claim data to help brand marketers identify areas where their co-pay program is underperforming. Based on these findings, the program is then course-corrected to garner greater impact. This paper examines the specific case of one manufacturer that, through optimization analysis, realized nearly $13 million in cost savings from corrections made to their programs.

Pharmaceutical brand marketers have traditionally viewed co-pay savings programs in a vacuum, as simply a mechanism that helps attract and retain patients and ultimately increase prescriptions filled. While this use of co-pay programs clearly generates positive results, these programs can be used for purposes that go well beyond that of providing affordable access to medications. By leveraging co-pay support programs as front-end patient acquisition tactics, marketers can use them as a means of engaging patients in the brand’s integrated and multifaceted marketing stream, thereby increasing opportunities for both brand success and improved patient outcomes.

Continued growth in the HUB space and a demonstrated need in the marketplace for integrated, patient-centric soultons, TrialCard has established TC Market Access as its dedicated HUB division.

Healthcare providers agree that the toughest challenge to treating patients is neither the effectiveness of their medication, nor issues with access and affordability. It's getting the patient to take their medicine as prescribed. And for the brand marketer, the new growth frontier resides on the sloping shoulders of patient adherence. This draws on new research to investigate how different branded promotional tactics affect adherence rates.

Small brands shouldn’t have to settle for standardized “out-of-the-box” patient access solutions. Small brands should demand that their unique, unmet challenges be solved by employing “team think” innovation and tireless customer service.

Prescription Abandonment can be solved. When a prescription is abandoned, nobody wins. The pharmaceutical brand loses a prescription. The pharmacist loses a customer. The patient loses the clinical benefit of a prescription medication that was prescribed for him/her. To win, pharmaceutical brands, pharmacists, and patients need an abandonment solution. RxSaver is the first solution for prescription abandonment.

Everyone knows the old saw that Willie Sutton said that he robbed banks because that was where the money was. There was a certain logic that the famed bankrobber had that is pretty relevant to the ways of Co-Pay, too – though before anyone panics about the parallel, let me explain! The healthcare industry has been wringing its collective hands for years about the problems surrounding “patient engagement.” Beyond the fact that no one has a really good definition of what constitutes patient engagement, most everyone agrees that if you have more patient engagement, you’ll achieve better outcomes.

With traditional pharmaceutical brands marketing channels narrowing, pharmacists are growing in their role as key health care providers for brand managers to reach.

Pharmaceutical brand marketers are facing a paradigm shift in the way they market patient access solutions. As they navigate through the dynamics of a regionalized market, shrinking budgets and the challenges of tactical implementation they require a consultative relationship with vendor providers. Can the pharmaceutical marketer really rely on 1 vendor to deliver customized, innovative solutions over the life of their brand?

TrialCard’s Affordable Care Act Task Force reviews the legal, regulatory, and business impact of the Affordable Care Act on the pharmaceutical industry.

Co-pay savings programs are often seen by pharmaceutical marketers as having an upper limit on how effective they can be in increasing brand performance. While they can certainly drive new patient starts and promote continued adherence, they aren’t without their challenges. One of the most prominent is that they are not infinitely scalable and their effectiveness will eventually reach a “leveling off” point. Brands desiring an upward surge in activity brought about by a co-pay offer are often left without an option – or are they? This white paper examines how adding an outbound virtual engagement solution enabled a top allergy brand to break through a program plateau to continue driving new patient starts.

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rare patients. TrialCard developed a proven model for making this critical match and has helped many patients gain access to the therapy they so desperately need. In a recent 2015–2016 program, TrialCard’s “Detective Model” approach to locating patients with a specific rare disease returned tenfold more leads back to the pharmaceutical sponsor than forecasted.

Virtual engagement strategies are evolving the way the pharmaceutical industry connects with key stakeholders. By using a blend of technology and experienced personnel to seamlessly connect brands to healthcare professionals, virtual engagement offers a solution to the trend of decreased in-person engagement opportunities via the traditional field representative model.

Pharmaceutical brand marketers consistently face two challenges in structuring their sales forces – penetrating hard to reach whitespace territories, and maintaining prescriptions in vacant territories during the time they are uncovered. Successfully addressing these two concerns can be the difference between driving increased brand performance and simply maintaining the status quo or worse, losing market share to competitors.

By utilizing data to understand specific reasons for non-adherence and the ideal timing, content, and channel for intervention, manufacturers can create more successful patient engagement strategies that help influence a shift toward better compliance with therapy.

Enter your email address and click submit to download your selected resources

Do you have questions? We’re here to help.
p: 877-343-1238 | e: info@trialcard.com

Are Co-Pay Accumulator Programs Affecting Your Brand?

Let TrialCard Help Assess the Risk for Your Patients






Learn More